Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Angiotensin II - La Jolla Pharmaceutical Company

Next Previous
Drug Profile

Angiotensin II - La Jolla Pharmaceutical Company

Alternative Names: ANGII; Angiotensin-II - LJPC; Angiotensin-II acetate; Giapreza; LJPC-501

Latest Information Update: 08 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Developer La Jolla Pharmaceutical Company; PAION
  • Class Angiotensins; Anti-infectives; Anti-inflammatories; Antihypotensives; Neuropeptides; Oligopeptides; Peptide hormones; Vasoconstrictors
  • Mechanism of Action Angiotensin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypotension
  • No development reported SARS-CoV-2 sepsis
  • Discontinued Hepatorenal syndrome

Most Recent Events

  • 08 Jul 2026 Launched for Hypotension in Norway (IV)
  • 30 Apr 2026 Paion Pharma plans a phase III trial for Hypotension (In neonates, In infants, In children, In adolescents) in France, Germany, Italy, Spain (Infusion), in April 2026 (CTIS2025-523750-14-00) (EUCT2025-523750-14-00)
  • 28 Nov 2024 No recent reports of development identified for clinical-Phase-Unknown development in SARS-CoV-2 sepsis in Belgium (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top